Cytokinetics, Incorporated (CYTK) Stock Price & Analysis

Cytokinetics, Incorporated (CYTK) closed at USD 62.33 on Thursday, October 22, 2026, down 0.84% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 62.33; the Oct 22, 2026 session ranged USD 61.94–64.07 on volume of 2,061,230 shares. Market capitalization is —, with a 52-week range of USD 54.3–88.31 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:50 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CYTK.md

Key facts (CYTK)

• Last four reported quarters (through Jun 30, 2026): revenue $67.7M, net income -$894M (-1321.1% margin), free cash flow -$581M (SEC filings).
• Total return with dividends: 1Y +8.4% vs S&P 500 +14.9%; 5Y +68.3% vs S&P 500 +80.3%.
• Next earnings: 2026-11-04, EPS estimate USD -1.41, revenue estimate $41.6M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CYTK)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (CYTK)

P/S 128.1x · EV/Sales 107.0x · FCF yield -6.70% · Earnings yield -10.32% · Net cash $1.42B · EV $7.24B

Analysts (CYTK)

Rating changes, last 120 days:

Total return (dividends reinvested) (CYTK)

CYTK revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

CYTK suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

Companies that name CYTK in their SEC reports

CYTK customer concentration

In the period ended Jun 30, 2026, 3 direct customers each accounted for at least 10% (36%, 34%, 23%) of revenue, per the company's 10-Q filed Aug 6, 2026. The company does not name them.

CYTK company outlook (results filed Aug 6, 2026)

• “The financial guidance does not include the effect of GAAP adjustments as may be caused by events that occur subsequent to publication of this guidance including, but not limited to, Business Development activities.”

Quoted word-for-word from the SEC 8-K results press release.

CYTK analyst estimates and revisions

CYTK options: expected move

Options price a move of about ±12.2% (±$7.63) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±6.1% on average.

30-day implied volatility 53.7% vs 29% realized over the last 30 trading days. Put/call ratio (volume) 0.19. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:50 UTC)

Technical Analysis (CYTK)

Nexqual's technical model rates CYTK "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:50 UTC.

Earnings (CYTK)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:50 UTC.

Financials & Fundamentals (CYTK)

Source: Nexqual, October 23, 2026 at 09:50 UTC.

Ownership (CYTK)

Source: Nexqual, October 23, 2026 at 09:50 UTC.

From Cytokinetics, Incorporated's Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our market research supports our belief that MYQORZO will be highly competitive amongst cardiac myosin inhibitors, potentially eventually achieving a greater than 50% market share in the United States but also growing the cardiac myosin inhibitor category overall.
• Finally, in January 2026 we submitted a supplemental NDA for MYQORZO to the FDA requesting to include the results of MAPLE-HCM, a Phase 3 randomized, double blind, active-comparator clinical trial of aficamten as monotherapy compared to metoprolol as a monotherapy in patients with obstructive HCM, in the label.
• We submitted a supplemental NDA to the FDA in January 2026 with the intent to include the results of MAPLE-HCM (a Phase 3 randomized, double blind, active-comparator clinical trial of aficamten as monotherapy compared to metoprolol as a monotherapy in patients with obstructive HCM) in the label.
• The FDA granted aficamten orphan drug designation for the treatment of symptomatic HCM in 2021.

Partnerships

• We are party to a collaboration and license agreement with Bayer Consumer Care AG, an affiliate of Bayer AG, for the exclusive development and commercialization of drug products containing aficamten in Japan, subject to certain reserved development rights of Cytokinetics to conduct ACACIA-HCM and CEDAR-HCM in Japan.
• We are party to a revenue interest agreement with RPI ICAV, the RP Aficamten RPA, pursuant to which RPI ICAV purchased rights to certain revenue streams from net sales of MYQORZO and any other future potential pharmaceutical products containing aficamten by us, our affiliates and our licensees.

Legal & Regulatory Risks (Item 1A, quoted)

• We cannot predict the likelihood, nature, or extent of health reform initiatives that may arise from future legislation or administrative action and cannot predict the effect of any of such initiatives on our future financial results or the value of our common stock.
• We may be subject to costly product liability or other liability claims and may not be able to obtain adequate insurance.
• The use of our drugs and drug candidates in clinical trials or by commercial patients may result in adverse events.
• We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:50 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt